PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26578773.
- Also identified by DOI 10.1073/pnas.1507540112 and PMC identifier 4655504.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Promyelocytic leukemia protein (PML) nuclear bodies (NBs) recruit multiple partners, including p53 and many of its regulators. NBs are believed to facilitate several posttranslational modifications and are key regulators of senescence. PML, the organizer of NBs, is expressed as a number of splice variants that all efficiently recruit p53 partners. However, overexpression of only one of them, PML IV, triggers p53-driven senescence. Here, we show that PML IV specifically binds ARF, a key p53 regulator. Similar to ARF, PML IV enhances global SUMO-1 conjugation, particularly that of p53, resulting in p53 stabilization and activation. ARF interacts with and stabilizes the NB-associated UBC9 SUMO-conjugating enzyme, possibly explaining PML IV-enhanced SUMOylation. These results unexpectedly link two key tumor suppressors, highlighting their convergence for global control of SUMO conjugation, p53 activation, and senescence induction.
Medical subject headings
- Cellular Senescence
- Cyclin-Dependent Kinase Inhibitor p16
- Nuclear Proteins
- SUMO-1 Protein
- Sumoylation
- Transcription Factors
- Tumor Suppressor Protein p53
- Tumor Suppressor Proteins